ABVC BioPharma, Inc.

NasdaqCM:ABVC Stock Report

Market Cap: US$6.2m

ABVC BioPharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ABVC?
Owner TypeNumber of SharesOwnership Percentage
Private Companies61,3560.501%
Institutions228,1921.86%
Hedge Funds622,8335.09%
Individual Insiders2,787,10722.8%
General Public8,544,97369.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 58.7%.

Top Shareholders

Top 25 shareholders own 30.2% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.16%
Eugene Jiang
998,760US$509.4k0%no data
7.12%
Shuling Jiang
872,209US$444.8k0%no data
5.09%
The Lind Partners, LLC
622,833US$317.6k0%2.98%
3.55%
Tsung-Shann Jiang
434,529US$221.6k0%no data
0.59%
Uttam Patil
72,428US$36.9k0%no data
0.58%
Geode Capital Management, LLC
71,607US$36.5k29.7%no data
0.47%
Yoshinobu Odaira
57,758US$29.5k0%no data
0.42%
Chun Chow
52,007US$26.5k0%no data
0.4%
LionGene Corporation
48,761US$24.9k0%no data
0.39%
Hsin-Hui Miao
48,072US$24.5k0%no data
0.38%
The Vanguard Group, Inc.
46,947US$23.9k0%no data
0.34%
Tsang Ming Jiang
41,994US$21.4k0%no data
0.34%
Yen-Hsin Chou
41,956US$21.4k0%no data
0.34%
Yu-Min Chung
41,943US$21.4k0%no data
0.34%
Norimi Sakamoto
41,854US$21.3k0%no data
0.34%
Chang-Jen Jiang
41,847US$21.3k0%no data
0.34%
Che-Wei Hsu
41,723US$21.3k0%no data
0.32%
Avantax Planning Partners, Inc.
39,000US$19.9k0%no data
0.19%
XTX Holdings Limited, Asset Management Arm
23,405US$11.9k23.6%no data
0.16%
Northern Trust Global Investments
19,135US$9.8k0%no data
0.11%
State Street Global Advisors, Inc.
12,900US$6.6k0%no data
0.1%
Two Sigma Securities, LLC, Asset Management Arm
12,397US$6.3k0%no data
0.079%
BioFirst Corporation
9,669US$4.9k0%no data
0.021%
Tower Research Capital Europe Limited
2,623US$1.3k-0.87%no data
0.014%
Rgene Corporation
1,687US$860.50%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 23:49
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ABVC BioPharma, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group
Marla MarinZacks Small-Cap Research